Zydus Lifesciences gets USFDA tentative nod for two generic drugs
Zydus Lifesciences said it has received tentative approvals from the US health regulator to market two generic drugs.
Zydus Lifesciences on Wednesday said it has received tentative approvals from the US health regulator to market two generic drugs -- used for lowering blood pressure and for controlling diabetes, in the American market.
The company has received tentative approval from the US Food and Drug Administration (USFDA) to market Bosentan Tablets for oral suspension in 32 mg strength, the drug maker said in a regulatory filing. Bosentan Tablet for oral suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients aged three years and older.
The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad, it said. As per the latest IQVIA data, Bosentan Tablets for oral suspension had annual sales of USD 16 million in the US.
In a separate filing, the company said it has also received tentative approval from USFDA to market canagliflozin tablets of strengths 100 mg and 300 mg. The canagliflozin tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This drug will be manufactured at the group's formulation manufacturing facility at Moraiya, the company added.
U.S. Secretary of State warns China against aiding Russia in Ukraine war
Miscreants throw stones at Owaisi's Delhi residence; Police files complaint
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Senior Citizen Latest FD Rates: Know what major banks like SBI, PNB, Canara Bank, HDFC Bank, ICICI Bank are providing on fixed deposits
Gratuity Calculator: Rs 38,000 as last-drawn basic salary, 5 years and 5 months of service; what will be gratuity amount?
Retirement Planning: In how many years your Rs 25K monthly SIP investment will grow to Rs 8.8 cr | See calculations
Top 5 Small Cap Mutual Funds with best SIP returns in 1 year: See how Rs 25,000 monthly investment has grown in each scheme
Top 7 SBI Mutual Funds With Best SIP Returns in 1 Year: Rs 25,000 monthly SIP investment in No.1 fund has jumped to Rs 3,58,404
SBI 5-Year FD vs MIS: Which can offer higher returns on a Rs 2,00,000 investment over 5 years? See calculations
12:30 PM IST